Waters Corporation to Present at the Jefferies Global Healthcare Conference
MILFORD, Mass., May 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.
WAT - Waters Corporation
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$402.75
DETAILS
HIGH:
$480.00
LOW:
$350.00
MEDIAN:
$401.00
CONSENSUS:
$402.75
UPSIDE:
18.52%
Stock News
Understanding Waters (WAT) Reliance on International Revenue
Examine the evolution of Waters' (WAT) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues
Waters crushes Q1 2026 estimates as revenues surge 91.5%; newly acquired BD units top targets early, and 2026 guidance moves higher.
Conrad Industries Is Worth The Volatile Waters The Industry Faces
Conrad Industries is a small-cap shipbuilder trading at a discount to heavy equipment peers, supported by recent revenue and profitability improvements. CNRD shifted from a $27 million net loss in 2023 to a $19.9 million net profit in 2024, with adjusted operating cash flow also turning positive. Despite a declining backlog and order softness, especially in energy, management remains cautiously optimistic for 2026 due to government and infrastructure demand.
Waters Corporation (WAT) Q1 2026 Earnings Call Transcript
Waters Corporation (WAT) Q1 2026 Earnings Call Transcript
Waters raises annual profit forecast as biosciences unit drives growth
Lab equipment maker Waters raised its annual profit forecast on Tuesday after beating quarterly estimates, driven by robust demand for drug development tools and the strong performance of its biosciences and diagnostics unit, acquired last year.
Waters (WAT) Beats Q1 Earnings and Revenue Estimates
Waters (WAT) came out with quarterly earnings of $2.7 per share, beating the Zacks Consensus Estimate of $2.31 per share. This compares to earnings of $2.25 per share a year ago.
Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results
First Quarter 2026 Highlights Total reported revenue of $1.267 billion exceeded the high end of the guidance range by $56 million, driven by strong outperformance in both organic revenue and the acquired businesses. Organic revenue grew 13% as reported and 11% in constant currency, exceeding the high end of the constant currency growth guidance range by 200 basis points – led by high-single-digit instrument growth and mid-teens chemistry growth within the Analytical Sciences Division.
Teleflex (TFX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Teleflex (TFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Waters (WAT) Beat Estimates Again in Its Next Earnings Report?
Waters (WAT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Waters (WAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Waters Corporation Schedules First Quarter 2026 Earnings Conference Call
MILFORD, Mass., April 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2026 financial results conference call on Tuesday, May 5, 2026 at 8:30 a.m.
Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
Delivers up to 4x faster chromatographic run times to accelerate decisions across discovery, development, and quality workflows.1,3 Achieves 10x improvement in absolute molar mass and extended sizing, without compromising resolution or analytical throughput.2 Reduces sample consumption by 30-50% and solvent use by approximately 40%.3 MILFORD, Mass., April 14, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced the launch of the Waters omniDAWN™ Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio.
Brown Lisle Cummings Inc. Increases Holdings in Waters Corporation $WAT
Brown Lisle Cummings Inc. grew its holdings in shares of Waters Corporation (NYSE: WAT) by 138.4% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,445 shares of the medical instruments supplier's stock after purchasing an additional 2,000 shares
Waters Stock Shoots Higher As FDA Clears At-Home Cervical Cancer Screening Kit
Waters Corporation (NYSE:WAT) shares are up on Wednesday as the company announced FDA clearance for its Onclarity HPV Self-Collection Kit, a significant step in expanding access to cervical cancer screening.
Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay
FDA-approved BD Onclarity™ HPV Assay is the most comprehensive screening tool for HPV in the U.S.1,4 with extended genotyping and end-to-end automated lab workflows. At-home self-collection reduces significant barriers for unscreened or under-screened individuals who make up approximately 60% of cervical cancer cases.3 Waters is establishing partnerships to enable broader nationwide access to the Onclarity™ HPV Self-Collection Kit for patients and prescribers to reduce cervical cancer risk.
ClearBridge Dividend Strategy Q1 2026 Portfolio Positioning
We bought four “new” holdings in the quarter. Two of the four — Blackstone and Otis — we have owned before. In IT, we exited Oracle and trimmed Broadcom. Our five-year investment in Oracle proved highly profitable as the company transitioned its business model from licensing to software-as-a-service. On the semiconductor side, we modestly reduced our position in Broadcom to fund our new investment in Taiwan Semiconductor.
Aberdeen Group plc Cuts Stock Position in Waters Corporation $WAT
Aberdeen Group plc decreased its holdings in shares of Waters Corporation (NYSE: WAT) by 3.6% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,863 shares of the medical instruments supplier's stock after selling 2,721 shares during the quarter. Aberdeen Group
Head-To-Head Review: Waters (NYSE:WAT) and ADB International Group (OTCMKTS:EQUR)
ADB International Group (OTCMKTS:EQUR - Get Free Report) and Waters (NYSE: WAT - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations. Valuation and Earnings This table compares ADB International
Head-To-Head Survey: Waters (NYSE:WAT) vs. Vicarious Surgical (NYSE:RBOT)
Waters (NYSE: WAT - Get Free Report) and Vicarious Surgical (NYSE: RBOT - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk. Insider and Institutional Ownership 94.0% of Waters shares are
Price Targets
Waters price target raised to $350 from $330 at Deutsche Bank
$350.00
(was $351.33)
Deutsche Bank
Waters price target raised to $425 from $400 at Barclays
$425.00
(was $349.53)
Barclays
Waters price target raised to $375 from $330 at UBS
$375.00
(was $352.64)
UBS
Waters price target raised to $387 from $362 at Baird
$387.00
(was $342.75)
Robert W. Baird
Waters price target lowered to $350 from $423 at Morgan Stanley
$350.00
(was $333.33)
Morgan Stanley
Waters price target lowered to $370 from $395 at UBS
$370.00
(was $327.59)
UBS
Waters price target lowered to $363 from $398 at Baird
$363.00
(was $326.16)
Robert W. Baird
Waters reinstated with an Overweight at Barclays
$400.00
(was $328.14)
Barclays
Waters initiated with a Buy at Guggenheim
$440.00
(was $394.97)
Subbu Nambi
·
Guggenheim
Waters price target raised to $415 from $385 at Wells Fargo
$415.00
(was $385.33)
Brandon Couillard
·
Wells Fargo
Wolfe Research Upgrades Waters Corp. (WAT) to Outperform
$480.00
(was $386.16)
Doug Schenkel
·
Wolfe Research
Waters initiated with an Equal Weight at Morgan Stanley
$423.00
(was $397.79)
Morgan Stanley
Waters initiated with a Buy at Rothschild & Co Redburn
$390.00
(was $318.35)
Natalya Davies
·
Redburn Partners
Waters price target lowered to $315 from $375 at Deutsche Bank
$315.00
(was $281.19)
Deutsche Bank
Waters price target lowered to $385 from $435 at Jefferies
$385.00
(was $285.59)
Jefferies
Waters Corp. (WAT) PT Raised to $465 at Scotiabank
$465.00
(was $352.70)
Sung Ji Nam
·
Scotiabank
Waters price target raised to $374 from $355 at Baird
$374.00
(was $339.02)
Catherine Ramsey Schulte
·
Robert W. Baird
Waters price target lowered to $400 from $430 at Bernstein
$400.00
(was $321.10)
Eve Burstein
·
Bernstein
Waters upgraded to Outperform from Neutral at Baird
$407.00
(was $367.79)
Catherine Ramsey Schulte
·
Robert W. Baird
CFRA Upgrades Waters Corp. (WAT) to Buy (midday)
$389.00
(was $347.31)
Jonathan Sakraida
·
CFRA